Technologies
Our strong product portfolio is supported through a range of patented technologies. Our cutting-edge technology platforms enable the discovery, development and production of vaccines, therapeutic proteins and gene therapy products.
What is PER.C6®?
PER.C6® is a human designer cell line for the development and large-scale manufacturing of biopharma products. In areas where Crucell does not aim to develop its own products, we license the technology to the biopharmaceutical industry. Currently over 60 companies and organizations have selected our PER.C6® technology to develop their own products across a wide range of therapeutic areas.
PER.C6® adaptable
Manufacturing of biopharmaceuticals has to take account of rapidly changing factors, such as rising volume demands and more stringent safety requirements. These shifts are a major challenge to conventional manufacturing platforms that have not adapted or become sufficiently flexible to cope with such changes. Our PER.C6® production cell line, however, is designed to meet these demands.
PER.C6® well protected
Our PER.C6® technology is protected by numerous patents. In addition, in order to benefit from our proprietary technology, potential customers not only need our know-how, but also our PER.C6® cells, which are only available from us under agreement. These agreements put certain restrictions on further dissemination and use of the PER.C6® cells. This combination of protections – patented know-how and the need to have access to the actual PER.C6® cells results in the PER.C6® technology being the best protected human cell technology in the world.
PER.C6® for protein and antibody production
We have a collaboration with DSM Biologics for the application of PER.C6® for proteins and antibodies. Together with DSM we license PER.C6® for proteins and antibodies as well as invest in further innovation of PER.C6®.
Working alongside DSM Biologics on the PER.C6® manufacturing platform, we believe that there is tremendous potential to reduce the production costs of monoclonal antibodies, whilst increasing yield resulting in more affordable treatments for patients.
In June 2008, we jointly announced that we had achieved a record-level titer of 27 grams per liter at harvest for an antibody product using PER.C6® at our PERCIVIA joint venture development center in Massachusetts, the USA.
To find out more about our five core technologies, please click on the links below: